Pharmigene, Inc. products

UGT1A1 gene promoter usually have 5-8 TA repeat, most people with 6/6 TA repeat, few people are 6/7 or 7/7 TA repeat, 7 TA repeat genotypes were named for the UGT1A1*28.

Clodpgrel, an antiplatelet agents is indicated for the reduction of thrombotic events as follows: Recent MI, Recent Stroke or Established Peripheral Arterial Disease. For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.